Study to Evaluate a High Intensity Focused Ultrasound (HIFU) Procedure in Patient With Liver Metastases

Neoplasm Metastasis Clinical Trial

— HIFU  

Official title:

A Phase I-II Study to Evaluate, in Patients Operated for a Hepatic Resection of Colorectal Liver Metastases, a High Intensity Focused Ultrasound (HIFU) Procedure: Feasibility, Safety and Accuracy.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01489787
• Other study ID #: HIFU
• Secondary ID: ET2009-068
• Status: Recruiting
• Phase: N/A
• First received: November 24, 2011
• Last updated: January 26, 2018
• Start date: March 2010
• Est. completion date: December 2019

Study information

• Verified date: January 2017
• Source: Centre Leon Berard
• Contact: Séverine METZGER
• Phone: +33 478 78 27 86
• Email: severine.metzger[@]lyon.unicancer.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the feasibility, safety and efficacy of High Intensity Focused Ultrasound (HIFU) patients undergoing hepatectomy for colorectal liver metastases. This is a phase I/II study.

Description:

Justification and interest of the study:

Colorectal liver metastases (CLM) are a major public health issue (16 000 deaths each year in France). To date, complete resection of CLM offers the only potential curative approach. However, only a minority of patients (10 to 20%) is candidates. 5-year survival rates after liver resection are ranged from 20 to 35%. Consequently, alternative locally targeted therapies (radiofrequency, cryotherapy, laser, microwave) have been developed and evaluated. Their use presents many limitations: invasive procedures requiring the intraparenchymal introduction of a probe, impossibility of an accurate monitoring in real-time, small size destruction, time-consuming, high recurrence rate. The development of a non-invasive and more accurate technique combined to surgery is required.

High Intensity Focused Ultrasound (HIFU) is a new approach, which enables to generate irreversible cell death through coagulative necrosis in a few seconds. There's no cooling effect of the perfusion because of the shortness of the phenomenon.

The surgical team of the Centre Leon Berard, in collaboration with the INSERM U556 one, has undertaken a research program on CLM treatment by HIFU. A new and very powerful device, without the previously named limitations, has been developed. Preclinical studies have revealed the interest, the feasibility and the safety of this process. These results enable considering preceding the program with an early clinical study.

Experimental design:

Prospective, monocentric phase I/II study evaluating a surgical medical device (SMD).

HIFU SMD will be evaluated in clinical conditions, in patients undergoing hepatectomy for colorectal liver metastases. Several HIFU "shootings" (the number will be function of the advancement of the study) will be performed on the liver witch will be resected

Objectives and main assessment criteria:

1. st part: Phase I - on the healthy liver to remove. Feasibility 1, Safety 2, Tolerance 3. Success = 1 Ability to perform shootings, supplementary duration of intervention < 30 minutes; 2 Asepsis, absence of lesion of nearly tissues; 3 Preservation of hemodynamic and respiratory constants.

2. nd part: Phase IIa - on the healthy liver to remove, distant then close to the vascular structures of the liver.

Ability of targeting shootings. Success = distance from the epicentre of the HIFU lesion to the mark previously positioned in the liver ≤ 5mm.

3. rd part: Phase IIb - on metastases to remove. Ability, by summation of HIFU lesions, to generate " macro-lesions " including a metastasis and insuring a sufficient safety margin in the healthy tissue.

Success = macro-lesion generated in negative margins.

Number of patients:

1. st part: The inclusion from 2 to 6 patients is required. The next step (phase II) will depend on:

• 1st analysis after 2 patients:

• If < 2 failures: continuation,

• If 2 failures: cessation of the study.

• 2nd analysis after 6 patients:

• If < 3 failures: continuation (phase II),

• If ≥ 3 failures: cessation.

2. nd part: Three patients will be successively included in each of the 2 landings (appendix 1):

• If no failure: continuation (2nd landing / Phase IIb),

• If ≤ 2 failures: + 3 patients,

• If > 2 failures on 6 patients: cessation,

• If ≤ 2 failures on 6 patients: continuation (2nd landing / phase IIb),

• If 3 failures: cessation.

3. rd part:

• p0 = 0.70 = upper limit of the success rate resulting in the inefficacy of HIFU multi-shootings.

• p1 = 0.90 = lower limit of the success rate resulting in the efficacy of HIFU shootings.

With a 5% risk of type I error and a 80% power, 28 metastases have to be targeted by HIFU in order to conclude in one-sided situation. Taking into account that an average of 1.5 metastases will be targeted in each patient, 20 patients will be enrolled. 24 observed successes will allow concluding in the reject of H0 to accept H1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 38
• Est. completion date: December 2019
• Est. primary completion date: October 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years old or more patient,

• Affected of hepatic metastasis of a colorectal cancer,

• Who must undergo a hepatectomy by laparotomy with the aim of the resection of hepatic metastasis,

• ECOG performance status (PS) = 1,

• Mandatory affiliation to a health security insurance,

• Written informed consent.

Exclusion Criteria:

• Having already undergone a major hepatic surgery (more than three segments) or biliary major (context of major iterative hepatic surgery),

• Having already undergone a major abdominal surgery with the exception of a colorectal surgery for the treatment of its primitive tumor (the surgery of the gall-bladder by laparoscopy for the deadline upper to 6 months do not constitute a criterion of not inclusion),

• Unable to be followed during the duration of the study,

• Pregnant or breast-feeding woman (a pregnancy test must be negative at the time of the inclusion in the study for the women in age to procreate; a method of reliable contraception must be used during the duration of the study).

Related Conditions & MeSH terms

• Neoplasm Metastasis

Intervention

Procedure:
• HIFU
The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient: One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma. One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient.
• HIFU
The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
• HIFU
Shootings will concern small metastases (= 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver. Several metastases can be treated in the same patient

Locations

Country	Name	City	State
France	Centre Léon Bérard	Lyon

Sponsors (3)

Lead Sponsor	Collaborator
Centre Leon Berard	Cancéropôle Lyon Auvergne Rhône-Alpes, National Cancer Institute, France

Country where clinical trial is conducted

France, 

References & Publications (26)

A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001 Mar 30;20(6):859-66. — View Citation

Antoniou A, Lovegrove RE, Tilney HS, Heriot AG, John TG, Rees M, Tekkis PP, Welsh FK. Meta-analysis of clinical outcome after first and second liver resection for colorectal metastases. Surgery. 2007 Jan;141(1):9-18. Epub 2006 Nov 17. — View Citation

Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2. — View Citation

Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A. In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res. 1992 Nov 15;52(22):6353-7. — View Citation

Coleman DJ, Lizzi FL, Driller J, Rosado AL, Burgess SE, Torpey JH, Smith ME, Silverman RH, Yablonski ME, Chang S, et al. Therapeutic ultrasound in the treatment of glaucoma. II. Clinical applications. Ophthalmology. 1985 Mar;92(3):347-53. — View Citation

Garcea G, Lloyd TD, Aylott C, Maddern G, Berry DP. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours. Eur J Cancer. 2003 Oct;39(15):2150-64. Review. — View Citation

Kinsey AM, Diederich CJ, Rieke V, Nau WH, Pauly KB, Bouley D, Sommer G. Transurethral ultrasound applicators with dynamic multi-sector control for prostate thermal therapy: in vivo evaluation under MR guidance. Med Phys. 2008 May;35(5):2081-93. — View Citation

Lee YJ, Wesley RA. Statistical contributions to phase II trials in cancer: interpretation, analysis and design. Semin Oncol. 1981 Dec;8(4):403-16. — View Citation

Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 1995 Aug 1;55(15):3346-51. — View Citation

Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006 Aug;244(2):254-9. — View Citation

Marquet F, Pernot M, Aubry JF, Montaldo G, Marsac L, Tanter M, Fink M. Non-invasive transcranial ultrasound therapy based on a 3D CT scan: protocol validation and in vitro results. Phys Med Biol. 2009 May 7;54(9):2597-613. doi: 10.1088/0031-9155/54/9/001. Epub 2009 Apr 8. — View Citation

Melodelima D, N'Djin WA, Parmentier H, Chesnais S, Rivoire M, Chapelon JY. Thermal ablation by high-intensity-focused ultrasound using a toroid transducer increases the coagulated volume. Results of animal experiments. Ultrasound Med Biol. 2009 Mar;35(3):425-35. doi: 10.1016/j.ultrasmedbio.2008.09.020. Epub 2008 Dec 10. — View Citation

Melodelima D, Prat F, Fritsch J, Theillere Y, Cathignol D. Treatment of esophageal tumors using high intensity intraluminal ultrasound: first clinical results. J Transl Med. 2008 Jun 5;6:28. doi: 10.1186/1479-5876-6-28. — View Citation

Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005 Aug;242(2):158-71. Review. — View Citation

N'Djin WA, Melodelima D, Parmentier H, Chesnais S, Rivoire M, Chapelon JY. Utility of a tumor-mimic model for the evaluation of the accuracy of HIFU treatments. results of in vitro experiments in the liver. Ultrasound Med Biol. 2008 Dec;34(12):1934-43. doi: 10.1016/j.ultrasmedbio.2008.04.012. Epub 2008 Jul 14. — View Citation

Parmentier H, Melodelima D, N'Djin A, Chesnais S, Chapelon JY, Rivoire M. High-intensity focused ultrasound ablation for the treatment of colorectal liver metastases during an open procedure: study on the pig. Ann Surg. 2009 Jan;249(1):129-36. doi: 10.1097/SLA.0b013e31818c70b6. Erratum in: Ann Surg. 2009 Sep;250(3):506. Hubert, Parmentier [corrected to Parmentier, Hubert]; David, Melodelima, David [corrected to Melodelima, David]; Apoutou, N'Djin [corrected to N'Djin, Apoutou]; Sabrina, Chesnais [corrected to Chesnais, Sabrina]; Yves, Chapelon Jean [corrected to Chapelon, Jean Yves]; Michel, Rivoire [corrected to Rivoire, Michel]. — View Citation

Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008 Jan;13(1):51-64. doi: 10.1634/theoncologist.2007-0142. Review. — View Citation

Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol. 2007 Feb;51(2):381-7. Epub 2006 May 2. — View Citation

Rivoire M, De Cian F, Meeus P, Négrier S, Sebban H, Kaemmerlen P. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer. 2002 Dec 1;95(11):2283-92. — View Citation

Seifert JK, Morris DL. Indicators of recurrence following cryotherapy for hepatic metastases from colorectal cancer. Br J Surg. 1999 Feb;86(2):234-40. — View Citation

Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int. 2006 Jan;97(1):56-61. — View Citation

Vaezy S, Fujimoto VY, Walker C, Martin RW, Chi EY, Crum LA. Treatment of uterine fibroid tumors in a nude mouse model using high-intensity focused ultrasound. Am J Obstet Gynecol. 2000 Jul;183(1):6-11. — View Citation

Vallancien G, Harouni M, Guillonneau B, Veillon B, Bougaran J. Ablation of superficial bladder tumors with focused extracorporeal pyrotherapy. Urology. 1996 Feb;47(2):204-7. — View Citation

Valtot F, Kopel J, Petit E, Moulin F, Haut J. [Treatment of refractory glaucoma with high density focused ultrasonics]. J Fr Ophtalmol. 1995;18(1):3-12. Review. French. — View Citation

Wu F, Wang ZB, Cao YD, Zhu XQ, Zhu H, Chen WZ, Zou JZ. "Wide local ablation" of localized breast cancer using high intensity focused ultrasound. J Surg Oncol. 2007 Aug 1;96(2):130-6. — View Citation

Wu F, Wang ZB, Chen WZ, Zhu H, Bai J, Zou JZ, Li KQ, Jin CB, Xie FL, Su HB. Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Ann Surg Oncol. 2004 Dec;11(12):1061-9. Epub 2004 Nov 15. — View Citation

* Note: There are 26 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	First step: Ability to shoot and supplementary duration of intervention, to use the medical device following requested asepsis procedures and no evidence of hurt on peripheral tissues and to keep vital signs stable		At the end of surgery (realized about 1 week after enrollment)
Primary	Phase IIa - First step: accuracy of shootings on a precise area	both the distance between the hurt epicentre generated by hifu and a mark. These sizes will be measured in mm during anatomopathological exam.	At the end of surgery (realized about 1 week after enrollment)
Primary	Phase IIb: possibility of = 15 shootings, safety margin = 5 mm in healthy liver.		At the end of surgery (realized about 1 week after enrollment)
Primary	Phase IIa - Second step: accuracy of shootings on a zone to be spared	between the hurt limit and a vessel border previously marked. These sizes will be measured in mm during anatomopathological exam.	At the end of surgery (realized about 1 week after enrollment)
Secondary	Phase I: adjust the probe position to different liver segments and patient physical structure.	The aim is to be free to generate a HIFU hurt in at least 80 % of the total liver volume	At the end of surgery (realized about 1 week after enrollment)
Secondary	Phase I: Possibility to set a stationary mark, at given depth, echographically detectable		At the end of surgery (realized about 1 week after enrollment)
Secondary	Phase I: Possibility to spot echographically a previously Patent Blue or Methylene blue marked vessel		At the end of surgery (realized about 1 week after enrollment)
Secondary	Phase I: Mean duration to achieve each step expressed in minutes(initialization, conditioning, targeting, shooting)		At the end of surgery (realized about 1 week after enrollment)
Secondary	Phase I: description of outline during perioperative echography	diameters, depth, volume	At the end of surgery (realized about 1 week after enrollment)
Secondary	Phase I: description of limits during anatomopathological analysis	diameters, depth, volume	At the end of surgery (realized about 1 week after enrollment)
Secondary	Phase I: distance between the mark / marked vessel and the hurt limits during anatomopathological analysis	Precise measure given in mm by the anatomopathologist	At the end of surgery (realized about 1 week after enrollment)
Secondary	Phase II: safety of the device	no evidence of hurt on peripheral tissues (Glisson capsule on the opposite side of the HIFU shootings entrance area, retro-peritoneal, retro-hepatic tissues and diaphragm	At the end of surgery (realized about 1 week after enrollment)
Secondary	Phase II: assessment of vital signs during shooting phase	hemodynamic, respiratory, body temperature	At the end of surgery (realized about 1 week after enrollment)
Secondary	Phase IIa: correlation between hurt perioperative echographic and postoperative macroscopic, measures	hurt dimensions comparison (diameters, depth, volume, etc. - in mm), blind-measured, with echography in a first time and in a second time, right after the resection, in anatomopathology	At the end of surgery (realized about 1 week after enrollment)